ArticleObesity surgery2024
Combination Therapy of Endoscopic Gastric Remodeling with GLP-1RA for the Treatment of MASLD.
Article in Obesity surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.
- Glucagon-Like Peptide-1 Receptor Agonists vs. Bariatric Endoscopy: A Systematic Review and Meta Analysis of Efficacy, Safety, and Metabolic Outcomes.Obesity surgery · 2026Pooled it
- Pooled it
- Beyond Weight Reduction: An Updated Systematic Review and Meta-Analysis of Metabolic Syndrome Components and Metabolic Dysfunction-Associated Steatotic Liver Disease Outcomes After Endoscopic Sleeve Gastroplasty.Journal of clinical medicine · 2026Review
- Endoscopic sleeve gastrectomyWorld journal of gastrointestinal pharmacology and therapeutics · 2025Review
- Endoscopic Bariatric Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanistic Insights and Metabolic Implications.Biomedicines · 2025Review
- Impact of metabolic endoscopy on fibrosis regression in steatotic liver disease.World journal of hepatology · 2025Review
- Endohepatology: Current perspectives and future directions.Hepatology communications · 2025Review
- Duodenal mucosal ablation: An emerging therapeutic concept for metabolic dysfunction-associated fatty liver disease.World journal of gastroenterology · 2025Article
- Endoscopic Sleeve Gastroplasty for Obesity Management Should Also Be a Consideration in Patients Unsuitable for Anti-obesity Medications.Obesity surgery · 2025Article
- Efficacy of anti-obesity medication (AOM) and endoscopic gastric remodeling (EGR): Analysis of combination therapy with optimal timing and agents.Endoscopy international open · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
purposeThe mainstay of treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) is weight loss. Endoscopic gastric remodeling (EGR) and glucagon-like peptide-1 receptor agonist (GLP-1RA) are effective weight loss therapies. This study aims to assess the effect of combining EGR with GLP-1RA on liver-related outcomes and weight profile. MATERIALS AND
methodsThis is a retrospective study of a prospectively collected registry of patients with MASLD and compensated advanced chronic liver disease (cACLD) who underwent EGR. Patients were categorized as (1) monotherapy: EGR alone and (2) combination therapy: GLP-1RA prescribed within 6 months prior to or after EGR. Outcomes included changes in noninvasive tests of hepatic fibrosis, weight profile, and insulin resistance status at 12 months.
resultsThirty patients (body mass index 40.7 ± 9.3 kg/m
conclusionsIn patients with MASLD and cACLD, combination of EGR with GLP-1RA is associated with greater improvements in hepatic fibrosis, weight profile, and insulin resistance compared to EGR alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.